Jouhou Koukai Services LLC and its businesses provide information and intelligence on the Japanese pharmaceutical market in the fields of drug and medical device approval, regulatory and pharmaceutical affairs, and market data.

- Tamiflu for about 12 millions patients; GlaxoSmithKline Japan KK
- Relenza for about 6 millions patients; Shionogi Seiyaku KK
Rapiacta (Peramivir) for about 1 million patients; and Daiichi-Sankyo KK
Inavir for about 1 million patients ... Anti-flu products in JAD Databases | Epidemiology consulting and data
3 generic versions of gemcitabine were launched in July as on August 3rd, a Health Ministry Advisory panel agreed to expand the indications so to include also ovarian cancer ...
Related report
Accredited Foreign Manufacturers
preview
Japan Orphan Drugs
preview
Japan Pricing & Reimbursement
preview
Japanese Generics and API
preview
Stigmatized Markets: ED
preview
Stigmatized Markets: Depression
preview
Stigmatized Markets: Genital Herpes
preview
Stigmatized Markets: Metabolic Syndrome
preview
Unapproved Medicinal Products (drug lag)
preview
Vaccines and Sera (vaccine gap)
preview
Jouhou Koukai Services LLC
The main information services and B2B e-commerce site of the Jouhou Koukai Services LLC - the leading provider of pharmaceutical development, regulatory and business intelligence information on the Japanese pharma and medical device market. The site contains the only English-language database of medicinal products approved in Japan from 1999 until present (Japan Approvals Database, JAD), free information resources and the online JKS Document Store (e-documents and e-books). Linked are the sites of the key businesses of JKS - primary market research (www.licenscape.com) and ehealth (www.ehealth-japan.com).